OncoMatch/Clinical Trials/NCT05735717
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Is NCT05735717 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for hematologic malignancy.
Treatment: Fludarabine · Busulfan · Melphalan · Rituximab · Levetiracetam · Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells · Thymoglobulin · Cyclophosphamide — This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Disease stage
Excluded: Stage CML BLAST CRISIS
CML blast crisis [excluded]
Demographics
Prior therapy
Cannot have received: autologous or allogeneic transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05735717 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous or allogeneic transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify